Andrew has a degree in Natural Sciences from Cambridge University, UK, specialising in genetics, with additional studies in molecular cell biology, biochemistry, chemistry, biology of cells, crystalline materials and mathematics.
He was subsequently awarded a DPhil by the University of Oxford for his research on the regulation of globin gene expression carried out at the Institute of Molecular Medicine, Oxford, UK. Andrew has experience of worldwide patent filing and prosecution on behalf of a wide range of clients, ranging from small academic and commercial clients to multi-national pharmaceutical companies.
Andrew’s practice has principally been before the European Patent Office and the UK Patent Office, but he also experience of worldwide patent prosecution including in the US, Australia, China, Japan and other territories. His work has principally been in the field of biotechnology (including genetics, molecular biology and cell biology) and has also covered a range of chemical and mechanical cases.
Representative technologies within Andrew’s experience include: protein- and DNA-based vaccines; novel DNA and protein molecules and associated therapeutic applications; therapeutic antibodies; stem cell technologies; transgenic animals and cloning methods in mammalian and avian species; tissue culture media and supplements; microbiological assays; microbiological cloning reagents and methods; medical devices; sterilisation and processing of pharmaceuticals; and a variety of simple mechanical devices.
Andrew is also involved in contentious work in Europe and the UK. In recent years, Andrew has represented several major clients in Opposition and Appeal proceedings before the European Patent Office including in Opposition proceedings in respect of CRISPR/Cas9 genome editing technology.
Andrew is a Senior Associate and also sits on the firm’s Operations Committee which is tasked with taking responsibility for making key business decisions and effecting such decisions across the firm.Get in touch today